Sandoz has a goal of increasing generic penetration in Ireland, which lags behind its European neighbors. As part of that objective, the firm has opted to take full control of its Rowex joint venture, based in County Cork.
Sandoz says it intends to continue to “invest significantly” in its Rowex joint venture in Ireland after acquiring the 50% of shares held by its partner Rowa Pharmaceuticals, following a successful three-decade partnership.
Based in Bantry, County Cork, the Rowex JV has evolved from its inception in 1993 to become one of Ireland’s “leading providers of generic and OTC medicines, supplying the Irish...
Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.
Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.
Teva will now market biosimilar Herceptin in both the US and Europe, after penning an agreement with Singaporean firm Prestige BioPharma for its Tuznue rival to the monoclonal antibody to treat HER2-positive breast cancer and HER2-positive metastatic stomach cancer.
Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.
Teva says it is now in the “accelerate growth” phase of its strategic roadmap, with global biosimilar launches set to help the firm achieve its goals.
Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.
Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.
